In a nod to the increasing interest in cannabidiol (CBD) products, Aeroflow Healthcare has unveiled Aeroflow Naturals, a division of CBD products.
The Food and Drug Administration currently has approved CBD only to treat epilepsy, but Aeroflow said it is confident further studies will demonstrate its efficacy elsewhere. Studies are looking at CBD oil for diseases ranging from Parkinson’s disease and multiple sclerosis to anxiety.
Aeroflow’s current products with CBD oil include sublingual oils, topical lotions/balms, capsules and vapes. It was important to Aeroflow to work with a trusted partner, Carolina Hemp Company, for the products, given the current lack of regulation in the market, said Jason Ivey, emerging markets specialist at Aeroflow Healthcare. Reliable suppliers provide a Certificate of Analysis to confirm lab testing that the products are free of pesticides, heavy metals and other contaminants.
“By purchasing CBD from reliable suppliers, consumers get peace of mind in knowing their products are safe, and their contents are accurately represented,” Ivey said.
Carolina Hemp Company has developed a reputation for safe products, he noted.
“Their experience in the hemp industry has proven to be an invaluable resource for Aeroflow while building the Naturals program to bring these products to our customers and patients,” Ivey said.
The products can provide nutritional support to the endocannabinoid system, increasing overall health and well-being, said Carolina Hemp Company CEO Randall Snyder.
Residents do not need prescriptions, he noted. Under the Agriculture Improvement Act of 2018, products derived from hemp containing less than 0.3% by weight of Delta-9 THC, and finished products produced from said hemp with less than 0.3% by weight of Delta-9 THC, are fine.
However, skilled nursing experts advise clinicians to talk to their head of state surveys. The Centers for Medicare & Medicaid Services declined to comment on CBD use.
From the May 1, 2019 Issue of McKnight's Long-Term Care News
